Shark cartilage extracts as antiangiogenic agents: Smart drinks or bitter pills?

Citation
D. Gingras et al., Shark cartilage extracts as antiangiogenic agents: Smart drinks or bitter pills?, CANC METAST, 19(1-2), 2000, pp. 83-86
Citations number
32
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
CANCER AND METASTASIS REVIEWS
ISSN journal
01677659 → ACNP
Volume
19
Issue
1-2
Year of publication
2000
Pages
83 - 86
Database
ISI
SICI code
0167-7659(200006)19:1-2<83:SCEAAA>2.0.ZU;2-G
Abstract
The use of crude cartilage for the treatment of human cancers remains a sub ject of controversy. In this brief commentary, we reviewed the current know ledge on the anticancer properties of cartilage. We then presented the prop erties of AE -941, a novel standardized water-soluble extract derived from shark cartilage that represents less than 5% of the crude cartilage. It is a multifunctional antiangiogenic product that contains several biologically active molecules. AE -941 is one of the few antiangiogenic drugs that is u nder phase III clinical investigation. It is currently evaluated in Europe and North America for the treatment of refractory renal cell carcinoma and in North America for metastatic non small cell lung cancer.